المؤلفون: J. G. Leviashvili, N. D. Savenkova, V. I. Guzeva, I. V. Anichkova, E. N. Suspitsin, Ж. Г. Левиашвили, Н. Д. Савенкова, В. И. Гузева, И. В. Аничкова, Е. Н. Суспицин

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 63, № 1 (2018); 90-95 ; Российский вестник перинатологии и педиатрии; Том 63, № 1 (2018); 90-95 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2018-63-1

مصطلحات موضوعية: лечение, Gitelman syndrome, hypomagnesemia, hypokalemia, alkalosis, cerebral calcifications, gene SLC12А3, diagnostics, treatment, синдром Гительмана, гипомагниемия, гипокалиемия, алкалоз, церебральные кальцификаты, ген SLC12А3, диагностика

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/625/600; OMIM: An online catalog of human genes and genetic disorders [Electronic resource]. Electronic data. Baltimore: Johns Hopkins Univ., 2015; Mode of access: http://www.omim.org/; Савенкова Н.Д., Папаян А.В., Левиашвили Ж.Г. Тубулопатии в практике педиатра. Руководство для врачей. Под ред. Н.Д. Савенковой, А.В. Папаяна. СПб: Левша 2006; 144.; Юрьева Э.А., Вельтищев Ю.Е., Игнатова М.С. Тубулопатии. В кн.: Детская нефрология. Руководство для врачей. Под ред. М. С. Игнатовой. М.: Мед. информ. агентство, 2011; 358–389.; Genetic diseases of the kidney. R.P. Lifton, S. Somlo, G.H. Giebisch (eds). Amsterdam, London: Elsevier: Acad. Press, 2009; 848.; Emmett M.,Sterns R.H, Forman J.P. Bartter and Gitelman syndromes [Electronic resource]. UpToDate. Electronic data, 2015; mode of access: http://www.uptodate.com/contents/ bartter-and-gitelman syndromes; Gil-Peña H., Mejia N., Alvarez-Garcia O., Loredo V., Santos F. Longitudinal growth in chronic hypokalemic disorders. Pediatr Nephrol 2010; 25(4): 733–737. DOI: org/10.1007/ s00467-009-1330-7; Левиашвили Ж.Г., Савенкова Н.Д., Левичева О.В., Снежкова Е.А. Катамнестическое наблюдение детей с синдромом Bartter и Gitelman. Нефрология 2013; 17(3): 80–87.; Devuyst O., Belge H., Konrad M., Jeunemaitre X., Zennaro M.C. Renal tubular disorders of electrolyte regulation in children. Gitelman syndrome. In: Pediatric Nephrology. E.D. Avner (ed.). Springer-Verlag, Berlin, Heidelberg, 2016; 1215–1221. DOI:10.1007/978-3-662-43596-0_34 1201; Das S.K., Ghosh A., Banerjee N., Khaskil S. Gitelman’s syndrome presenting with hypocalcemia, basal ganglia calcification and periodic paralysis. Singapore Med J 2012; 53: e222–e224.; Peters M., Jeck N., Reinalter S., Leonhardt A., Tönshoff B., Klaus G. et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Amer J Med 2002; 112(3): 183–190.; Viering D.H.H.M., de Baaij J.H.F., Walsh S.B., Kleta R., Bockenhauer D. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol 2017; 32(7): 1123–1135. DOI:10.1007/s00467-016-3416-3; Beltagi A.El., Norbash A., Vattoth S.Novel brain MRI abnormalities in Gitelman syndrome. Neuroradiol J 2015; 28(5): 523-528.DOI:10.1177/1971400915609340; Koulouridis E., Koulouridis I. Molecular pathophysiology of Bartter’s and Gitelman’s syndromes. World J Pediatr 2015; 11(2): 113–125. DOI:10.1007/s12519-015-0016-4; Sardani Y., Qin K., Haas M., Aronson A.J., Rosenfield R.L. Bartter syndrome complicated by immune complex nephropathy: case report and literature review. Pediatr Nephrol 2003; 18(9): 913–918.; Seyberth H.W., Schlingmann K.P. Bartter and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 2011; 26(10): 1789–1802. DOI:10.1007/s00467-011-1871-4; Simon D. B., Nelson-Williams C., Bia M. J., Ellison D., Karet F.E., Molina A.M. et al. Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genet 1996; 12(1): 24–30. DOI:10.1038/ng0196-24; Monnens L., Bindels R., Grünfeld J.P. Gitelman syndrome comes of age. Nephrol Dial Transplant1998; 13(7): 1617–1619.; Devarajan, P., Langman C.B. Pediatric Bartter syndrome [Electronic resource]. Medscape 2011; mode of access: http://www.emedicine.com/ped/TOPIC210.HTM; Riveira-Munoz E., Chang Q., Godefroid N., Hoenderop J.G., Bindels R.J., Dahan K. et al. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Amer Soc Nephrol 2007; 18(4): 1271–1283. DOI:10.1681/ASN.2006101095; Tsutsui H., Hamano T., Kawaura Y.,Inaba S., Miyamori I.,YasujimaM, et al. Case of Gitelman syndrome associated with idiopathic intracranial hypertension. Intern Med 2011; 50: 1493–1496. DOI:10.2169/internalmedicine.50.5305.; Quinlan C.S., Walsh J.C., Moran A.M., Moran C., O’Rourke S.K. Gitelman syndrome. A rare presentation mimicking cauda equina syndrome. J Bone Joint Surg Br 2011; 93: 266–268. DOI:10.1302/0301-620X.93B2.25700; Gandi K., Prasad D., Malhotra V., Agrawal D. Gitelman’s syndrome presenting with hypocalcemic tetany and hypokalemic periodic paralysis, case report. India Saudi J Kidney Dis Transpl 2016; 27(5): 1026–1028.; Gierth M., Banas B., Burger M. Metabolic alkalosis. In: Urology at a glance.A.S. Merseburger, M.A. Kuczyk, J.W. Moul (eds). Heidelberg, New York, Dordrecht, London: Springer, 2014; 77–80.; Vargas-Poussou R., Dahan K., Kahila D., Venisse A., Riveira-Munoz E., Debaix H. et al. Spectrum of Mutations in Gitel-man Syndrome. J Am SocNephrol 2011; 22(4): 693–703. DOI:10.1681/ASN.2010090907; Игнатова М.С., Длин В.В. Роль генетики в развитии детской нефрологии. Рос вестн перинатол и педиатр 2015; 60(3): 6–9.; Николаева Е.А. Значение достижений медицинской генетики для решения проблемы нарушения развития у детей. Рос вестн перинатол и педиатр 2016; 61(2): 5–11. DOI:10.21508/1027-4065-2016-61-2-5-11; https://www.ped-perinatology.ru/jour/article/view/625

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/625
https://doi.org/10.21508/1027-4065-2018-63-1-90-95

المؤلفون: A. A. Kashintsev, G. A. Yanus, N. Yu. Kokhanenko, V. M. Moiseenko, M. D. Hanevich, L. D. Roman, A. G. Ievleva, A. P. Sokolenko, E. N. Suspitsin, A. I. Budovskiy, A. V. Togo, N. M. Volkov, R. V. Fadeev, M. S. Dinikin, A. K. Ivanova, K. G. Shostko, E. N. Imyanitov, А. А. Кашинцев, Г. А. Янус, Н. Ю. Коханенко, В. М. Моисеенко, М. Д. Ханевич, Л. Д. Роман, А. Г. Иевлева, А. П. Соколенко, Е. Н. Суспицин, А. И. Будовский, А. В. Того, Н. М. Волков, Р. В. Фадеев, М. С. Диникин, А. К. Иванова, К. Г. Шостко, Е. Н. Имянитов

المصدر: Siberian journal of oncology; № 5 (2013); 39-44 ; Сибирский онкологический журнал; № 5 (2013); 39-44 ; 2312-3168 ; 1814-4861 ; undefined

مصطلحات موضوعية: наследственный рак молочной железы и яичников, BRCA1, BRCA2

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/237/239; Al-Sukhni W., Rothenmund H., Borgida A.E. et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma//Hum. Genet. 2008. Vol. 124. P. 271-278; Aretini P., D’Andrea E., Pasini B. et al. Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation//Breast Cancer Res. Treat. 2003. Vol. 81. P. 71-79; van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J. et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary//J. Med. Genet. 2005. Vol. 42. P. 711-719; Axilbund J.E., Argani P., Kamiyama M. et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients//Cancer Biol. Ther. 2009. Vol. 8. P. 131-135; Barrow E., Robinson L., Alduaij W. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations//Clin. Genet. 2009. Vol. 75. P. 141-149; Brose M.S., Rebbeck T.R., Calzone K.A. et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program//Natl. Cancer Inst. 2002. Vol. 94. P. 1365-1372; Chalasani P., Kurtin S., Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation//JOP. 2008. Vol. 9. P. 305-308; Couch F.J., Johnson M.R., Rabe K. et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer//Cancer Res. 2005. Vol. 65. P. 383-386; Couch F.J., Johnson M.R., Rabe K.G. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer//Cancer Epidemiol. Biomarkers Prev. 2007. Vol. 16. P. 342-346; Dagan E. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer//Genet. Test. 2008. Vol. 12. P. 267-271; Ferlay J., Shin H.R., Bray F. et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 29/07/2013; Ferrone C.R., Levine D.A., Tang L.H. et al. BRCAgermline mutations in Jewish patients with pancreatic adenocarcinoma//J. Clin. Oncol. 2009. Vol. 27. P. 433-438; Figer A., Irmin L., Geva R. et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel//Br. J. Cancer. 2001. Vol. 84. P. 478-481; Fogelman D.R., Wolff R.A., Kopetz S. et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer//Anticancer Res. 2011 Vol. 31. P. 1417-1420; Ghiorzo P., Fornarini G., Sciallero S. et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families//J. Med. Genet. 2012. Vol. 49. P. 164-170; Ghiorzo P., Pensotti V., Fornarini G. et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy//Fam. Cancer. 2012. Vol. 11. P. 41-47; Goggins M., Sehutte M., Lu J. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas//Cancer Research. 1996. Vol. 56. P. 5360-5364; Goldstein A.M., Chan M., Harland M. et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL//Cancer Res. 2006. Vol. 66. P. 9818-9828; Groen E.J., Roos A., Muntinghe F.L. et al. Extra-intestinal manifestations of familial adenomatous polyposis//Ann. Surg. Oncol. 2008. Vol. 15. P. 2439-2450; Hahn S.A., Greenhalf B., Ellis I. et al. BRCA2 germline mutations in familial pancreatic carcinoma//J. Natl. Cancer Inst. 2003. Vol. 95. P. 214-221; van der Heijden M.S., Yeo C.J., Hruban R.H., Kern S.E. Fanconi anemia gene mutations in young-onset pancreatic cancer//Cancer Res. 2003. Vol. 63. P. 2585-2588; Hollestelle A., Wasielewski M., Martens J.W., Schutte M. Discovering moderate-risk breast cancer susceptibility genes//Curr. Opin. Genet. Dev. 2010. Vol. 20. P. 268-276; Imyanitov E.N., Moiseenko M.V. Drug therapy for hereditary cancers//Hered. Cancer Clin. Pract. 2011. Vol. 9. P. 1-16; Iqbal J., Ragone A., Lubinski J. et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers//Br. J. Cancer. 2012. Vol. 107. P. 2005-2009; Johannsson O., Loman N., Möller T. et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers//Eur. J. Cancer. 1999. Vol. 35. P. 1248-1257; Jones S., Hruban R.H., Kamiyama M. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene//Science. 2009. Vol. 324. P. 217; Kastrinos F., Mukherjee B., Tayob N. et al. Risk of pancreatic cancer in families with Lynch syndrome//JAMA. 2009. Vol. 302. P. 1790-1795; Klein A.P. Genetic susceptibility to pancreatic cancer//Mol. Carcinog. 2012. Vol. 51. P. 14-24; Kim D.H., Crawford B., Ziegler J., Beattie M.S. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations//Fam. Cancer. 2009. Vol. 8. P. 153-158; Lal G., Liu G., Schmocker B. et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations//Cancer Res. 2000. Vol. 60. P. 409-416; Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature//Mutat. Res. 2009. Vol. 681. P. 299-307; Lawniczak M., Gawin A., Białek A. et al. Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?//Pol. Arch. Med. Wewn. 2008. Vol. 118. P. 645-649; van Lier M.G., Wagner A., Mathus-Vliegen E.M. et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations//Am. J. Gastroenterol. 2010. Vol. 105. P. 1258-1264; Lowery M.A., Kelsen D.P., Stadler Z.K. et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCAmutation: clinical descriptors, treatment implications, and future directions//Oncologist. 2011. Vol. 16. P. 1397-1402; Lubinski J., Phelan C.M., Ghadirian P. et al. Cancer variation associated with the position of the mutation in the BRCA2 gene//Fam. Cancer. 2004. Vol. 3. P. 1-10; Lucas A.L., Shakya R., Lipsyc M.D. et al. High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions//Clin. Cancer Res. 2013. Vol. 19. P. 3396-3403; Maisonneuve P., Marshall B.C., Lowenfels A.B. Risk of pancreatic cancer in patients with cystic fibrosis//Gut. 2007. Vol. 56. P. 1327-1328; Mocci E., Milne R.L., Méndez-Villamil E.Y. et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry//Cancer Epidemiol. Biomarkers Prev. 2013. Vol. 22. P. 803-811; Moiseyenko V.M., Volkov N.M., Suspistin E.N. et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer//Med. Oncol. 2013. Vol. 30. P. 54-57; Moran A., O’Hara C., Khan S. et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations//Fam. Cancer. 2012. Vol. 11. P. 235-242; Murphy K.M., Brune K.A., Griffin C. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%//Cancer Res. 2002. Vol. 62. P. 3789-3793; Ozçelik H., Schmocker B., Di Nicola N. et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients//Nat. Genet. 1997. Vol. 16. P. 17-18; Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview//Nat. Rev. Gastroenterol. Hepatol. 2009. Vol. 6. P. 699-708; Real F.X., Malats N., Lesca G. et al. Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer//Gut. 2002. Vol. 50 P. 653-657; Rebours V., Lévy P., Ruszniewski P. An overview of hereditary pancreatitis//Dig. Liver Dis. 2012. Vol. 44. P. 8-15; Risch H.A., McLaughlin J.R., Cole D.E. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada//J. Natl. Cancer Inst. 2006. Vol. 98. P. 1694-1706; Roberts N.J., Jiao Y., Yu J. et al. ATM mutations in patients with hereditary pancreatic cancer//Cancer Discov. 2012. Vol. 2. P. 41-46; Saufferlein T., Bachet J.B., van Cutsen E. et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2012. Vol. 23. P. 33-40; Slater E.P., Langer P., Fendrich V. et al. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families//Fam. Cancer. 2010. Vol. 9. P. 335-343; Sokolenko A.P., Iyevleva A.G., Mitiushkina N.V. et al. Hereditary breast-ovarian cancer syndrome in Russia//Acta Naturae. 2010. Vol. 2. P. 31-35; Sokolenko A.P., Rozanov M.E., Mitiushkina N.V. et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia//Fam. Cancer. 2007. Vol. 6. P. 281-286; Solomon S., Das S., Brand R., Whitcomb D.C. Inherited pancreatic cancer syndromes//Cancer J. 2012. Vol. 18. P. 485-491; Stadler Z.K., Salo-Mullen E., Patil S.M. et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer//Cancer. 2012. Vol. 118. P. 493-499; The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers//J. Natl. Cancer Inst. 1999. Vol. 91. P. 1310-1316; Thompson D., Easton D.F. Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers//J. Natl. Cancer Inst. 2002. Vol. 94. P. 1358-1365; Tonin P., Weber B., Offit K. et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families//Nat. Med. 1996. Vol. 2. P. 1179-1183; Tulinius H., Olafsdottir G.H., Sigvaldason H. et al. The effect of a single BRCA2 mutation on cancer in Iceland//J. Med. Genet. 2002. Vol. 39. P. 457-462; Walsh T., King M.C. Ten genes for inherited breast cancer//Cancer Cell. 2007. Vol. 11. P. 103-105; Wang X., Szabo C., Qian C. et al. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers//Cancer Res. 2008. Vol. 68. P. 971-975; Wolpin B.M., Chan A.T., Hartge P. et al. ABO blood group and the risk of pancreatic cancer//J. Natl. Cancer Inst. 2009. Vol. 101. P. 424-431; https://www.siboncoj.ru/jour/article/view/237; undefined

الاتاحة: https://www.siboncoj.ru/jour/article/view/237